{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:36:36Z","timestamp":1772120196966,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.amjmed.2019.06.029","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T01:54:38Z","timestamp":1562810078000},"page":"95-99.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins \u2013 Confirmation from PCSK9 Inhibitor Studies"],"prefix":"10.1016","volume":"133","author":[{"given":"Tanya","family":"Salvatore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Marchioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9841","key":"10.1016\/j.amjmed.2019.06.029_bb0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2019.06.029_bb0010","doi-asserted-by":"crossref","unstructured":"Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 2002;23(24):1908\u201321.","DOI":"10.1053\/euhj.2002.3236"},{"issue":"5","key":"10.1016\/j.amjmed.2019.06.029_bb0015","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(04)00734-3","article-title":"Stroke prevention, blood cholesterol, and statins","volume":"3","author":"Amarenco","year":"2004","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1016\/j.amjmed.2019.06.029_bb0020","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.amjmed.2019.06.029_bb0025","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.amjmed.2019.06.029_bb0030","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjmed.2019.06.029_bb0035","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/archinte.1996.00440100050007","article-title":"Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease","volume":"156","author":"Marchioli","year":"1996","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.amjmed.2019.06.029_bb0040","first-page":"434","article-title":"Primary and secondary prevention of ischemic cardiopathy. A meta-analysis with meta-regression as a biologic mechanism: reflections on clinical practice based on scientific evidence","volume":"28","author":"Marchioli","year":"1998","journal-title":"G Ital Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2019.06.029_bb0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000016035","article-title":"Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials","volume":"10","author":"Di Mascio","year":"2000","journal-title":"Cerebrovasc Dis"},{"issue":"9602","key":"10.1016\/j.amjmed.2019.06.029_bb0050","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.amjmed.2019.06.029_bb0055","first-page":"198","article-title":"Cholesterol-lowering interventions and stroke","volume":"55","author":"De Caterina","year":"2010","journal-title":"insights from a meta-analysis of randomized controlled trials J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2019.06.029_bb0060","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2016.03.024","article-title":"Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT","volume":"248","author":"De Caterina","year":"2016","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.amjmed.2019.06.029_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.amjmed.2019.06.029_bb0070","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/jama.1970.03180070069012","volume":"214","author":"The Coronary Drug Project. Initial findings leading to modifications of its research protocol","year":"1970","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.amjmed.2019.06.029_bb0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","volume":"231","author":"Clofibrate and niacin in coronary heart disease","year":"1975","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.amjmed.2019.06.029_bb0080","first-page":"1069","article-title":"Report from the Committee of Principal Investigators","volume":"40","author":"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate","year":"1978","journal-title":"Br Heart J"},{"issue":"6","key":"10.1016\/j.amjmed.2019.06.029_bb0085","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.amjmed.2019.06.029_bb0090","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2019.06.029_bb0095","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0735-1097(01)01783-1","article-title":"Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST)","volume":"39","author":"Sawayama","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.amjmed.2019.06.029_bb0100","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.amjmed.2019.06.029_bb0105","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"issue":"25","key":"10.1016\/j.amjmed.2019.06.029_bb0110","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.amjmed.2019.06.029_bb0115","doi-asserted-by":"crossref","first-page":"e2286","DOI":"10.1212\/WNL.0000000000007454","article-title":"Lipid levels and the risk of hemorrhagic stroke among women","volume":"92","author":"Rist","year":"2019","journal-title":"Neurology"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319305649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319305649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:19:12Z","timestamp":1757582352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934319305649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0002934319305649"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.06.029","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736190939.793562706","asserted-by":"object"}]},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins \u2013 Confirmation from PCSK9 Inhibitor Studies","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}